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Abstract: The causal link between chronic hepatitis C and glycometabolic alterations has been
confirmed by much biochemical, clinical, and epidemiological research work, but what is still
controversial is the long-term clinical impact of sustained virologic response (SVR) achieved by
direct-acting antiviral agents (DAAs) on patients with type 2 diabetes mellitus (DM). The aim of this
paper is to summarize the biochemical and clinical consequences to DM of DAA-based therapy for
hepatitis C virus (HCV) infection. An electronic search of Embase, PubMed, MEDLINE, Ovid, and
the Cochrane Database of Systematic Reviews was conducted for publications assessing whether
clearance of HCV achieved by interferon (IFN)-free antiviral therapy determines significant changes in
glycometabolic control and clinical outcomes of diabetic patients. A beneficial effect of SVR obtained
by DAA therapy on DM prevention and the short-term outcome of glycometabolic alterations are
acknowledged by most of the studies. Whether this effect is maintained over the long term with a
significant clinical impact on diabetic and liver disease is still a matter of debate.
Keywords: Hepatitis C virus; chronic hepatitis C; insulin resistance; diabetes mellitus; impaired
fasting glucose; direct-acting antiviral agents; cirrhosis; antidiabetic therapy
1. Introduction
Hepatitis C virus (HCV) infection has been associated with the development of extrahepatic
manifestations [1], including type 2 diabetes mellitus (DM). Several reviews and meta-analyses [2–5]
have shown a higher prevalence of DM in patients with chronic hepatitis C (CHC) than in controls.
The processes by which HCV induces DM have not been completely understood, but evidence [6–10]
suggests that insulin resistance (IR) is the main mechanism, triggered by several pathogenic causes
such as proinflammatory cytokines, chemokines, and immune-mediated actions leading to the final
impairment of insulin receptors (Figure 1). Interestingly, whole-body insulin sensitivity is affected
in patients with CHC [11], but antiviral therapy with direct-acting antiviral agents (DAAs) seems to
predominantly improve peripheral insulin sensitivity [12].
According to a recent meta-analysis [13], in patients with CHC treated with interferon (IFN), the
achievement of a sustained virologic response (SVR) significantly reduces the incidence of IR during
follow-up; this is reflected in decreased frequency of DM in the years following viral eradication.
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Figure 1. Theoretical explanation of the pathogenesis of hepatitis C virus-induced insulin resistance. 
The virus directly or indirectly, through the induction of interleukin 6 (IL-6) and/or tumor necrosis 
factor-alpha (TNF-𝛼), determines the protoeosomal degradation of the insulin receptor substrate (IRS 
1 and 2) by inducing suppression of cytokine signalling (SOCS); the consequent downregulation of 
phosphoinositide 3-kinase (PI3-K) causes reduced GLUT4 (glucose carrier) transmembrane 
expression, leading to the final inhibition of insulin signalling. 
According to a recent meta-analysis [13], in patients with CHC treated with interferon (IFN), the 
achievement of a sustained virologic response (SVR) significantly reduces the incidence of IR during 
follow-up; this is reflected in decreased frequency of DM in the years following viral eradication. 
What is still controversial is the role played by SVR in HCV-positive patients with glucose 
intolerance (impaired fasting glucose, IFG) or established DM. In fact, the mechanism by which viral 
eradication would determine an improvement of the biochemical parameters of HCV-positive 
patients with DM or IFG has not yet been clarified. In addition to the uncertainty about how viral 
eradication would act on glycemic dysmetabolism, there is a lack of prospective studies with 
appropriate follow-up on the outcomes of diabetic patients achieving SVR. With the advent of DAAs 
and consequent high SVR rates, several observational studies [14–27] and one meta-analysis [28] 
suggested a significant clinical impact of SVR on DM outcomes; however, two of them [18,19], despite 
reporting significant initial amelioration, did not observe long-term improvement in glycemic control 
and some other studies [29–33] failed to find any significant glycometabolic changes. Controversies 
still exist regarding the post-SVR outcome of DM; current data are not sufficient to determine whether 
the acquired effect observed at SVR (significant decrease in fasting glycemia and glycated 
hemoglobin, HbA1c) persists over time and if it induces relevant variations regarding antidiabetic 
therapy. Finally, the influence of DAA-induced SVR on the long-term outcome of DM in diabetic 
patients remains largely unknown. 
In order to address these issues, we performed a systematic review of pertinent studies 
published up to 30 June 2019. 
2. Experimental Section 
An electronic search of Embase, PubMed, MEDLINE, Ovid, and the Cochrane Database of 
Systematic Reviews was conducted for publications, with no language and study type restrictions, 
up to 30 June 2019. The keywords used were: chronic hepatitis C, diabetes mellitus, diabetes, type 2 
diabetes mellitus, insulin resistance, cardiovascular diseases, renal insufficiency, retinopathy, 
microangiopathy, hepatitis, chronic hepatitis C, hepatitis C virus, HCV, meta-analysis, systematic 
review, review, direct-acting antiviral agents, cirrhosis, hepatocellular carcinoma (HCC). All the 
Figure 1. Theoretical explanation of the pathogenesis of hepatitis C virus-induced insulin resistance.
The virus directly or indirectly, through the induction of interleukin 6 (IL-6) and/or tumor necrosis
factor-alpha (TNF-α), determines the protoeosomal degradation of the insulin receptor substrate
(IRS 1 and 2) by inducing suppression of cytokine signalling (SOCS); the consequent downregulation of
phosphoinositide 3-kinase (PI3-K) causes reduced GLUT4 (glucose carrier) transmembrane expression,
leading to the final inhibition of insulin signalling.
What is still controversial is the role played by SVR in HCV-positive patients with glucose
intolerance (impaired fasting glucose, IFG) or established DM. In fact, the mechanism by which viral
eradication would determine an improvement of the biochemical parameters of HCV-positive patients
with DM or IFG has not yet been clarified. In addition to the uncertainty about how viral eradication
would act on glycemic dysmetabolism, there is a lack of prospective studies with appropriate follow-up
on the outcomes of diabetic patients achieving SVR. With the advent of DAAs and consequent high
SVR rates, several observational studies [14–27] and one meta-analysis [28] suggested a significant
clinical impact of SVR on DM outcomes; however, two of them [18,19], despite reporting significant
initial amelioration, did not observe long-term improvement in glycemic control and some other
studies [29–33] failed to find any significant glycometabolic changes. Controversies still exist regarding
the post-SVR outcome of DM; current data are not sufficient to determine whether the acquired effect
observed at SVR (significant decrease in fasting glycemia and glycated hemoglobin, HbA1c) persists
over time and if it induces relevant variations regarding antidiabetic therapy. Finally, the influence of
DAA-induced SVR on the long-term outcome of DM in diabetic patients remains largely unknown.
In order to address these issues, we performed a systematic review of pertinent studies published
up to 30 June 2019.
2. Experimental Section
An electronic search of Embase, PubMed, MEDLINE, Ovid, and the Cochrane Database of
Systematic Reviews was conducted for publications, with no language and study type restrictions,
up to 30 June 2019. The keywords used were: chronic hepatitis C, diabetes mellitus, diabetes,
type 2 diabetes mellitus, insulin resistance, cardiovascular diseases, renal insufficiency, retinopathy,
microangiopathy, hepatitis, chronic hepatitis C, hepatitis C virus, HCV, meta-analysis, systematic
review, review, direct-acting antiviral agents, cirrhosis, hepatocellular carcinoma (HCC). All the articles
obtained were evaluated and accepted if they met one or more of the following criteria: (1) data on
the incidence of IR and/or DM in the follow-up of patients treated with DAAs; (2) sufficient data to
establish the glycometabolic response in HCV-positive diabetic patients after DAA therapy; (3) data on
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the incidence of DM-related events in the follow-up of diabetic patients treated with DAAs; and (4)
data on the incidence of liver-related events in the follow-up of diabetic patients treated with DAAs.
We excluded studies that involved patients without IR and/or DM and conference abstracts.
Data were independently extracted by two researchers (D.G.R. and M.S.) and discrepancies were
resolved by the third reviewer (G.M.S.). The following information was collected from each study: first
author, year of publication, country of origin, study and design type (randomized controlled double
blind/open label trial, observational cohort prospective/retrospective study, cross-sectional study, case
report), control group (untreated patients or nonresponders), total sample size, gender, age (mean and
range), glycemic and HbA1c levels pre/post DAA therapy and during post-SVR follow-up, length of
post-SVR follow-up, number and percentage of patients with reduced antidiabetic therapy, and number
and type of DM-related and liver-related events in diabetic patients during post-SVR follow-up.
Five issues regarding glycometabolic control in diabetic patients with CHC who were successfully
treated with DAAs were identified, and the following pertinent questions were posed:
(1) Does SVR achieved by DAAs significantly prevent the onset of IR and DM?
(2) Does HCV clearance with DAAs lead to significant improvement of glycometabolic control in
patients with DM? If so, is this control maintained over the long term?
(3) Does SVR-related glycometabolic improvement induce de-escalation/withdrawal of
antidiabetic therapy?
(4) Do DAA-induced glycemic changes determine a significant clinical impact on the outcome of
DM and its complications?
(5) What is the clinical impact of DAA-induced SVR on the incidence of HCC in diabetic patients?
3. Results and Discussion
3.1. Does SVR Achieved by DAAs Significantly Prevent the Onset of Insulin Resistance and DM?
In the pre-DAA era, several reviews and meta-analyses [13,34,35] showed that SVR impacted the
incidence of IR and DM in cured patients. This observation was confirmed by most of the studies
conducted on patients who were treated with DAAs (Table 1).
Table 1. Impact of DAA treatment on insulin resistance in nondiabetic HCV patients.
Author, Year (ref.) Type ofStudy Design
No. of
Patients
with SVR
No. of
Control
Patients
HOMA-IR
Change (p) Follow-Up
Salomone et al.
2018 [36] Observational Prospective 32 N.A. −1.4 (<0.001) 12 weeks
Elhelbawy et al.
2019 [37] Observational Prospective
465 (24%
with DM) 46
−1.09
(<0.001) 12 weeks
Adinolfi et al.
2018 [38] Case-control Prospective 68 65
−2.66
(<0.001) 12 weeks
Gualerzi et al.
2018 [39] Observational Prospective 82 N.A.
−0.62
(<0.001) 12/24 weeks
Andrade et al.
2018 [40] Observational Prospective 75 N.A. −0.76 (0.02) 12 weeks
Meissner et al.
2015 [41]
Phase 2
clinical trial Prospective 33 17
Not
significant 36 weeks
Doyle et al.
2019 [42] Observational Prospective 23 N.A. −0.3 (0.32) 24 weeks
DAA, direct-acting antiviral agent; HCV, hepatitis C virus; SVR, sustained virologic response; N.A., not available;
HOMA-IR, homeostatic assessment of insulin resistance; DM, diabetes mellitus.
Adinolfi and colleagues [38] prospectively evaluated the changes concerning IR in nondiabetic
patients with HCV genotype 1 and advanced hepatic fibrosis treated or untreated with DAAs. Patients
achieving SVR showed a significant reduction in blood glucose and insulin levels and a concomitant
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improvement in insulin sensitivity, which did not occur in untreated patients. Improvement of IR
appeared independent of fibrosis severity and body mass index (BMI) value. Gualerzi et al. [39]
prospectively analyzed 82 HCV-RNA-positive nondiabetic patients, most with cirrhosis, who were
treated with DAAs. Before and immediately after antiviral therapy, all underwent a standard
oral glucose tolerance test (OGTT); the OGTT-derived indices were homeostasis model assessment
(HOMA)-IR and insulin sensitivity index (ISI). The authors showed baseline glucose metabolism
abnormalities in about 55% of patients; significant improvements of HOMA-IR and ISI were found
in both prediabetic patients and normal glucose-tolerant patients. Salomone and colleagues [36]
studied 32 patients with genotype 1 and cirrhosis treated by DAAs, all with OGTT-documented IFG.
After therapy, all patients achieved SVR and significant improvement of the glycemic curve and ISI,
despite there being no change of BMI and lifestyle. Similar results were described by a recent Brazilian
study [40] that monitored HOMA-IR to verify changes in IR in patients with CHC treated with DAAs.
HOMA-IR was significantly improved only in nondiabetic patients with a pretherapy HOMA-IR
> 2.5. According to Elhelbawy and colleagues [37], a statistically significant difference in 12-week
post-treatment HOMA-IR was found in 465 sustained responders compared to 46 nonresponders
(1.9 versus 3.33, p = 0.001). Contradictory results were reported by an American [41] and a Canadian [42]
study: In the first, 60 HCV-positive patients, genotype 1 (most of them nondiabetic or prediabetic),
were treated with sofosbuvir and ribavirin for 24 weeks and followed for an additional 24 weeks
post-therapy; SVR was achieved by 70% of patients. According to the authors, HOMA-IR did not
significantly change in either sustained responders or nonresponders. However, the results may
have been affected by the incomplete adherence to fasting in blood sampling reported by the authors.
Similar data were reported by Doyle et al. [42]: 23 of 24 HCV-positive patients obtained SVR without
significant variation of their HOMA-IR.
Regarding the impact of DAAs on the incidence of DM (Table 2), recent studies performed on
large series of patients of the US Veterans Administration reported conflicting data; in the study of
Butt and colleagues [43], 21279 diabetic patients treated with DAAs and 4764 nondiabetic patients
treated with pegylated interferon (PEG-IFN)/ribavirin (RBV) were included, as well as a control group
composed of untreated nondiabetic patients. The incidence of DM was recorded, although without
providing the follow-up data, in the various subgroups and a significant reduction of DM onset was
observed in patients treated with DAAs (9.89/1000 person-years, 95% confidence interval (CI) 8.7–11.1)
compared to untreated patients (20.6, 95% CI 19.6–21.6, p < 0.001) and those treated with PEG-IFN/RBV
(19.8, 95% CI 18.3–21.4), p < 0.001). The difference between the two types of treatment can be explained
by the different efficacy rates of viral eradication obtained with IFN compared to IFN-free treatment.
Moreover, these rates were not reported by the study, which merely describes an overall SVR rate of
78.82%. In multivariate analysis, the reduction in the risk of developing DM in patients treated with
DAAs was quantified as 47% (relative risk (RR) 0.53, 95% CI 0.46–0.63, p < 0.0001) and the unfavorable
predictive factors were ethnic origin (black or Hispanic), male sex, high BMI, and advanced liver fibrosis.
Surprisingly, the results of this study contrast with those of a study [44] performed on identical series
(only veterans, predominantly male) composed of 41711 patients with SVR and 3549 nonresponders
after therapy with DAAs. After a mean follow-up of about 2 years, no statistically significant difference
regarding the incidence of DM between the two groups was observed (21.04/1000 patients per year
versus 23.11/1000 patients per year, hazard ratio (HR) = 0.98, 95% CI = 0.81–1.19, p = 0.86). Of interest,
an American study [45] conducted in the IFN era on similar patient series showed that viral clearance
had a significant impact on the incidence of diabetic disease. Like all retrospective studies performed
on large databases, these studies have limitations: identification of co-factors influencing the onset of
DM was not optimal; in particular, variations of lifestyle (diet, physical exercise) or habits (smoking)
were not recorded. A hypothesis to explain the discrepancy could be the difference in the duration
of the average follow-up, which was much longer in the study by Mahale et al. [45]. It is therefore
likely that, with comparable follow-up, the results might not have been all that different, given that
nonresponders generally show a strong tendency toward DM onset with the worsening of liver fibrosis.
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Table 2. Incidence of DM in HCV patients treated with DAAs.
Author, Year
(Reference)
Type of
Study Design
No. of
Patients
with
SVR
No. of
Control
Patients
DM
Incidence in
SVR
Patients
DM
Incidence in
Control
Patients
p-Value Follow-Up
Butt et al.
2019 [43] Observational Retrospective 21279 4764
9.9/1000
persons/year
20.9/1000
persons/year <0.001 6 years
El-Serag et al.
2019 [44] Observational Retrospective 41711 3549
21.0/1000
persons/year
23.1/1000
persons/year 0.86 2 years
Li et al. 2018
[46] Observational Retrospective 3748 1397 6.2% 21.7% 0.0003 3.7 years
Roccaro et al.
2019 [47] Observational Retrospective 31 225 9.7% 23.0% 0.02
41.2
months
DM, diabetes mellitus; HCV, hepatitis C virus; DAAs, direct acting antiviral agents; SVR, sustained virologic response.
Other studies on less selected and therefore more representative series showed a significant
reduction of the onset of de novo DM in HCV-positive patients with SVR. In the study of Li and
colleagues [46], 5127 nondiabetic patients treated with DAA were followed up: the incidence of DM
after an average follow-up of 3.7 years was found to be 6.2% in sustained responders compared to
21.7% in nonresponders (HR = 0.79; 95% CI: 0.65–0.96). A study [47] conducted on liver transplant
patients with HCV-positive cirrhosis showed that SVR obtained with DAAs induced a significant
reduction in post-transplantation DM (HR = 0.40, p = 0.048). However, this decrease was found to be
particularly marked in patients with SVR obtained before transplantation (9.7% versus 23%, HR = 0.30,
p = 0.046), which adds another element in favor of the proposal to administer antiviral therapy before
transplantation rather than after.
In conclusion, studies that evaluated the effect of DAA-induced SVR on the incidence of IR and
DM in sustained responders seem to confirm what was already observed in the IFN era. However,
it should be noted that comparing the effects of IFN treatment with those of DAAs is not relevant
since they represent two completely different mechanisms of viral eradication. Last but not least,
although the majority of the above-mentioned studies indicate a beneficial effect of SVR in reducing
the risk of onset of IR/DM, appropriate follow-up is still lacking. Therefore, definite conclusions
cannot be drawn on the lasting efficacy of antiviral therapy with DAAs with regard to the incidence of
glycometabolic abnormalities.
Data coming from further follow-up studies will be crucial to determine beyond any reasonable
doubt whether viral eradication significantly reduces the onset of IR and DM, resulting in an important
benefit to global public health.
3.2. Does HCV Clearance with DAAs Lead to Significant Improvement of Glycometabolic Control in Patients
with DM? If so, is This Control Maintained over the Long Term?
A recent review with a meta-analysis [28] demonstrated and quantified the improvement of
glycometabolic control in diabetic patients with CHC achieving SVR after treatment with DAAs. Eleven
publications were considered and discussed by the review but only five met the inclusion requirements
for the meta-analysis. Regarding the variation of HbA1c levels, an average decrease of –0.45% was
found (95% CI: –0.60 to –0.30%, p < 0.001) with strong heterogeneity between the studies (χ2 = 20.4,
p < 0.001). Glycemic values were evaluated by three studies [15,20,21]: A significant reduction of
–22 mg/dL (95% CI: –41.61 to –2.44 mg/dL, p = 0.03) was observed, with wide heterogeneity among the
studies (χ2 = 35.82, p < 0.001). According to the reported data, the number of published studies that
agreed with the glycometabolic amelioration induced by SVR was higher than the number of studies
that disagreed with this hypothesis.
Actually, several studies (Table 3) show significant improvement in glycemic levels and HbA1C
at the end of DAA therapy, compared to a few (Table 4) that did not show any significant change in
glycometabolic control.
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Table 3. Studies reporting significant glycometabolic improvement in DAA-treated HCV-positive
patients with SVR.
Author, Year
(Reference)
Type of
Study Design
No. of
Diabetic pts
Mean
Glycemic
Change (p)
Mean HbA1c
Level Change (p) Follow-Up
Ciancio et al.
2018 [15] Observational Prospective 101
−18.0 md/dL
(0.002) −0.5% (<0.001) 12 weeks
Abdel
Alem et al.
2017 [20]
Observational Retrospective 65 −11.5 mg/dL(0.005) –0.5% (<0.001) 24 weeks
Dawood et al.
2017 [21] Clinical trial Open label 378
−23.4 mg/dL
(N.A.) −0.45% (N.A.) 12 weeks
Bejg et al.
2018 [24] Observational Retrospective 38
–19.8 mg/dL
(0.01) −0.2% (0.03) 24–44 weeks
Pavone et al.
2016 [27] Observational Retrospective 27
−52.7 mg/dL
(0.0007) −2.0% (0.02) 8 weeks
Weidner et al.
2018 [18] Observational Retrospective 28
−22 mg/dL
(0.04) −0.29% (0.04) 0–44 weeks
Gilad et al.
2019 [17] Observational Retrospective 122
Not
determined −0.6% (0.001) 1.5 years
Hum et al.
2017 [14] Observational Retrospective 2435
Not
determined −0.37% (0.03)* 48 weeks
Morales et al.
2016 [22] Observational Retrospective 23
Not
determined −0.53% (<0.005) 24 weeks
Ikeda et al.
2017 [23] Observational Prospective 13
Not
determined −0.2% (<0.01) 12 weeks
Pashum et al.
2016 [26] Case report – 1
Not
determined −5.8% (N.A.) 24 weeks
Li et al. 2019
[19] Observational Retrospective/Prospective192
Not
determined −2.3 (<0.001) 24 weeks
Fabrizio et al.
2017 [25] Observational Retrospective 59
–20 mg/dL
(<0.001) Not determined 24 weeks
Drazilova et al.
2018 [16] Observational Retrospective 88
−21 mg/dL
(<0.0001) Not determined 12 weeks
DAA, direct acting antiviral agent; HCV, hepatitis C virus; SVR, sustained virologic response; HbA1c, hemoglobin
A1c; N.A., not available; * −0.13%, p = 0.01 when adjusted by multiple regression analysis.
Table 4. Studies reporting no significant glycometabolic improvement in DAA-treated HCV-positive
patients with SVR.
Author, Year
(Reference)
Type of
Study Design
No. of
Diabetic pts
Mean
Glycemic
Change (p)
Mean HbA1c
Level Change (p) Follow-Up
Stine et al. 2017
[31] Observational Retrospective 26
Not
determined −0.25% (0.27) 12 weeks
Saab et al. 2018
[29] Observational Retrospective 30 N.A. (0.32) Not determined 27 months
Teegen et al.
2019 [30] Observational Retrospective 32
Not
determined −0.7% (0.1) 31 months
Chaudhury et al.
2018 [32] Observational Prospective 41
−6 mg/dL
(0.21) −0.1% (0.29) 28 months
Huang et al.
2017 [33] Clinical trial Prospective 13
Not
determined –0.1% (0.17) 3−15 months
DAA, direct acting antiviral agent; SVR, sustained virologic response; HbA1c, hemoglobin A1c; N.A., not available.
Two studies [18,19], although demonstrating significant glycometabolic improvement at SVR, did
not confirm this improvement over the long term.
The number of recruited patients is extremely variable, ranging from a minimum of 13 to a
maximum of 2435 patients, and methods regarding outcome evaluation vary. The follow-up is not
homogeneous: it ranges from a minimum of 12 weeks to a maximum of 60 months. A decrease of HbA1c
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of at least 0.5% when compared to baseline values is usually considered a significant improvement of
the glycemic state [48], but this cutoff point was adopted by only three studies [17,20,21].
In the study by Ciancio et al. [15], baseline glycemic and HbA1c levels as well as the type of
antidiabetic therapy were comparable between the sustained virologic responders (group 1) and
non-SVR-/untreated patients (group 2). Diabetic patients with SVR showed a significant decrease
in glucose (152.4 ± 56.4 mg/dL versus 134.3 ± 41.3 mg/dL, p = 0.002) and HbA1c (6.9% versus 6.4%,
p < 0.001) values at 12 weeks from the end of therapy; no significant glucose (145.3 ± 30.2 versus
140.0 ± 47.9 mg dL, p = 0.710) and HbA1c (7.0% versus, 7.2%, p = 0.780) reduction was observed
among group 2 patients. Abdel Alem and colleagues [20] found a significant improvement of glycemic
(103 mg/dL versus 113 mg/dL, p = 0.005) and HbA1c (6.4% versus 6.9%, p < 0.001) levels at 24 weeks
from the end of therapy. Subgroup analysis showed that the decrease in glucose values occurred
mainly in patients treated with oral hypoglycemic agents (100 mg/dL versus 116.5 mg/dL, p = 0.008)
while decreased HbA1c was present in both insulin-treated and oral therapy patients (6.2% versus 6.7%,
p = 0.007 and 6.5% versus 7.0%, p = 0.001, respectively). Dawood et al. [21] stratified diabetic patients
with SVR (378 patients, 94.5%) into two groups based on the presence (292 patients, 77.2%) or absence
(86 patients, 22.8%) of glycometabolic improvement to assess baseline predictive factors. Improvement
was defined as a reduction in fasting blood glucose of at least 20 mg/dL or an HbA1c level of at least 0.5%.
Genetic predisposition, advanced stage of liver fibrosis, and duration of diabetic disease were negative
predictive factors for glycometabolic amelioration. After three months of DAA therapy, average
glycemic and HbA1c levels decreased from 184.5 ± 27.9 to 136.5 ± 22.5 mg/dL and from 8.1 ± 0.4% to
7.3 ± 0.3%, respectively, in the group with significant glycometabolic improvement. In the study by
Gilad et al. [17], a decrement of 0.6% (95% CI: 0.2–0.9, p < 0.01) in HbA1c was found 1.5 years after the
end of therapy with DAAs (8.4% ± 1.9% versus 7.8% ± 1.7%). By defining glycometabolic improvement
as a reduction of HbA1c (with or without reduction of antidiabetic therapy) or antidiabetic therapy
(even without a significant variation of HbA1c), the authors showed an amelioration rate of 34%.
The predictors of glycometabolic improvement were the presence of at least one antidiabetic therapy,
the type of antidiabetic therapy (insulin), and higher creatinine levels. Hum and colleagues [14]
retrospectively evaluated 2435 diabetic patients with HCV treated with DAAs; viral eradication was
obtained in about 90% of cases and 255 patients were nonresponders. A significant decrease in HbA1c
levels was observed only in patients with SVR and high pretherapy levels of HbA1c (>7.2%) compared
to nonresponders (0.98 ± 1.4% versus 0.65 ± 1.5%, p = 0.02). In sustained responders with pretherapy
HbA1c levels < 7.2% and in cirrhotic patients, no significant reduction was observed. These conclusions
cannot be easily reproducible as the patients were American veterans, predominantly obese (average
BMI > 30) males (98%) with genotype 1 (>99%). Limiting factors of the study were the inability
to verify any other therapies besides the antidiabetic one and the impossibility of identifying any
changes in lifestyle during follow-up, with all factors potentially influencing glycometabolic control.
Pavone et al. [27] measured glycemic and HbA1c levels before and during treatment with DAAs in
29 diabetic patients, demonstrating an average reduction in fasting plasma glucose of 52.86 mg/dL
(p = 0.007) and HbA1c of −1.95% (p = 0.021). Fabrizio and colleagues [25] confirmed these results with
a larger series (59 patients) and a more robust follow-up, but evaluating only the glycemic values. The
same approach was adopted by Drazilova and colleagues [16] who studied glycemic trends in a series
of Slovak patients treated with DAAs: only diabetics or patients with impaired fasting glucose (IFG)
showed a significant decrease in fasting plasma glucose (FPG) after achieving SVR. Ikeda et al. [23]
measured HbA1c levels in 36 Japanese patients treated with DAAs before and after therapy; of these,
13 were diabetic. Globally, HbA1c levels decreased from 5.85% to 5.65% (p < 0.01), but the study did
not report glycometabolic data concerning diabetic patients only. Morales et al. [22] retrospectively
analyzed 60 patients with HCV treated and cured with sofosbuvir-based combination therapy (IFN
was also used in 35%). Out of 60 patients, 23 (38.3%) were diabetic; data on HbA1c trends were
available in 39 patients. A significant decrease of this parameter was observed 3–6 months after
therapy (6.13% versus 6.66%, p < 0.005) without a significant average weight loss. Data regarding
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HbA1c changes were not reported according to the presence/absence of DM, but the authors showed
a larger drop in HbA1c among diabetic compared to nondiabetic patients, although this was not
statistically significant. Weidner and colleagues [18] evaluated over time glycemic and HbA1c values
of 281 HCV-RNA-positive patients treated with DAAs, 28 of which had DM. Significant reductions in
glycemia (from 168 ± 8.7 mg/dL to 146 ± 9.2 mg/dL, p = 0.04) and HbA1c (p = 0.0367) were observed
in diabetic patients with SVR 6 months after the end of therapy, but this effect was observed only in
noncirrhotic patients. Finally, Pashun et al. [26] published a case report regarding an obese woman with
chronic hepatitis C and DM poorly controlled with insulin therapy, showing a significant decrease in
HbA1c levels and a reduction in insulin dosage after DAA-induced SVR, maintained up to 15 months
after the end of therapy, despite the observed weight increase.
The effect of antiviral therapy with DAAs on diabetic patients has also been studied in the liver
transplant setting [24,29,30]. Beig and colleagues [24] observed a significant decrease of HbA1c levels
(from 35.5 ± 4.3 mmol/mol to 33.3 ± 3.6 mmol/mol, p = 0.03) at 44 weeks from the end of treatment
in 91 liver transplant recipients with recurrent HCV infection treated with DAAs. Unfortunately, it
is not possible to establish from the reported data the HbA1c reduction in the 26 diabetic patients
treated and cured by DAAs, even though the authors report a 40% decrement of DM treatment. These
conclusions were not confirmed by Saab and colleagues [29] in 30 transplanted diabetic patients
treated with DAAs; no statistically significant differences in glycemic values were observed before
antiviral therapy and during follow-up. HbA1c levels were not evaluated in this study. In the study by
Teegen et al. [30], 32 HCV-positive diabetic patients on insulin therapy who underwent orthotopic
liver transplantation (OLT) achieved SVR after DAA therapy; HbA1c levels were monitored from
baseline until the end of follow-up (30.6 months), with a nonstatistically significant decrease (from
7.1% to 6.4%, p = 0.098). However, two patients discontinued insulin therapy and a decrease in the
cumulative insulin dosage (from 55.3 U/d to 38.2 U/d, p = 0.009) was recorded at the end of treatment
in the absence of weight changes.
In addition to the studies by Saab et al. [29] and Teegen et al. [30], other publications [31–33]
showed no significant improvement in glycometabolic control after viral eradication with DAAs. Of
these, two recruited a mixed cohort of diabetic and nondiabetic patients [32,33]; in one case, glycemic
and HbA1c levels referred to the entire cohort [33]. Stine et al. [31] did not show any significant changes
in HbA1c levels 12 weeks after SVR in 26 diabetic patients treated with DAAs (from 7.3% to 7.1%,
p = 0.268). Furthermore, 31% of patients had to increase their dosage of insulin therapy. Chaudhury
and colleagues [32] found no significant differences between baseline and follow-up values of glycemia
and HbA1c in sustained responders and nonresponders. Of the 42 patients with SVR, only 7 (3%)
reduced their dosage of antidiabetic therapy. Huang et al. [33] evaluated HbA1c levels in a mixed
cohort of diabetic (13, 21.7%), prediabetic (11, 18.3%), and normoglycemic (36, 60%) patients before
starting therapy and 12 weeks after the end of treatment without finding significant variations (from
5.6 ± 0.6% to 5.5 ± 0.6%, p = 0.17). These three studies show important methodological limitations;
the number of patients recruited was rather low (range 13–42); in one study [32], it is not possible to
extrapolate the glycemic and HbA1c values according to the presence of DM or not; and, despite the
reported absence of glycometabolic improvement, the reduction of antidiabetic therapy was observed
only in diabetic patients with SVR.
Once it is established that most of the current evidence agrees that SVR induces a significant
improvement in glycometabolic control in a substantial proportion of patients, the next question is whether
this effect is maintained over the long term. Data addressing this question are scant, heterogeneous, and
often contradictory. Most studies [15,16,20–23,25,27,31,41] report an average follow-up ranging from end
of treatment to 24 weeks after discontinuation of therapy; publications [14,17–19,24,26,30,32] with longer
follow-up (>24 weeks from the end of the therapy) provide discrepant data. In the case report by
Pashun et al. [26], HbA1c levels continued to improve until the last follow-up check (15 months after the
end of treatment) despite weight gain and progressive tapering of insulin therapy. In the study of Hum
and colleagues [14], glycometabolic improvement involved only noncirrhotic diabetic patients with
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pretherapy levels of HbA1c≥ 7.2%, but this improvement was maintained up to 15 months after the end
of treatment. Gilad et al. [17] followed their patients with SVR up to 1.5 years post-therapy and observed
maintenance of the reduction in HbA1c levels, with no differences between cirrhotic and noncirrhotic
patients; in particular, in the secondary analysis regarding patients who improved from a diabetological
point of view (≥0.5% reduction in HbA1c levels with or without modification of antidiabetic therapy
or reduction/suspension of antidiabetic therapy in the absence of significant changes in HbA1c), 71%
showed sustained improvement. Similar data were reported by Beig and colleagues [24] in a population
of liver transplant recipients: maintenance of glycometabolic improvement in 38 diabetic patients
was observed up to 44 months after obtaining SVR, with sustained cessation of antidiabetic therapy
in about 40% of patients. According to Weidner et al. [18], the significant reduction in HbA1c levels
was maintained until the 24th follow-up month only in noncirrhotic diabetic patients, whereas in
cirrhotic diabetic patients, this improvement disappeared from the 12th month of follow-up. It should
be noted that of the 28 diabetic patients considered, only 22 had baseline data and of these, only 9
were followed up until 24 months after the end of therapy. Of the 73 diabetic patients treated with
DAAs included in the study of Li and colleagues [19], 66 (90.4%) achieved SVR; in the 7 nonresponding
diabetic patients and the 73 untreated HCV-positive diabetic patients who acted as a control group,
HbA1c levels remained unchanged over the long term, while in the 66 patients with SVR, a triphasic
course was observed: a significant reduction up to 6 months from the end of therapy, a rebound in
the following months, and a stabilization of the pretherapy levels from the 30th to 60th follow-up
month. The retrospective/prospective study design was rather complex, with some limitations: in
the general analysis, patients treated with IFN were also included and there were no data regarding
possible confounding factors such as changes in lifestyle and adherence to antidiabetic therapy.
Chaudhury et al. [32] prospectively followed 42 HCV-RNA-positive diabetic patients treated and cured
with DAAs (except one), with a mean follow-up of 28 months after the end of therapy, and compared
the mean HbA1c values in sustained responders before treatment and at the end of follow-up, without
observing significant modifications of this parameter. Similar results were obtained by Teegen and
colleagues [30] in a population of transplanted patients with a mean follow-up of 30.6 months.
In conclusion, an improvement of glycometabolic control at the end of therapy or in the immediate
post-therapy months in diabetic patients, or only in some subgroups, as reported by Hum and
colleagues [14] and by Weidner et al. [18], is reported by the vast majority of studies published so far.
Whether this beneficial effect is maintained over the long term is still a matter of debate. For this reason,
large prospective cohort studies with appropriate analysis of possible confounding factors (smoking
status, steatosis staging, BMI variations, physical exercise, adherence to antidiabetic therapy) are
urgently needed to establish the persistence of such an amelioration. Meanwhile, we can hypothesize
that subgroups of patients will benefit from viral eradication in the long term also on the metabolic
side, but on the other hand, it is reasonable to think that a significant proportion of diabetic patients
with SVR, probably patients with advanced cirrhosis and/or a long duration of diabetic disease, will
not experience lasting benefits from viral clearance and the effectiveness of glycometabolic control will
have to be based on lifestyle and adherence to antidiabetic therapy. This observation suggests a point
of no return where the impact of viral eradication on the outcome of diabetic disease is minimal or
irrelevant; therefore, it is extremely important to quickly identify HCV-positive diabetic patients in
order to start antiviral therapy without delay, so as to stop fibrotic progression, on the one hand, and to
reduce the risk of the occurrence of extrahepatic complications related to DM on the other.
3.3. Does SVR-Related Glycometabolic Improvement Determine De-Escalation/Withdrawal of Antidiabetic
Therapy?
Few studies have analyzed this aspect (Table 5) and often do not specify the type of modified
treatment or criteria leading to the reduction/withdrawal.
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Table 5. Studies reporting de-escalation/withdrawal of antidiabetic therapy in HCV-positive diabetic
patients with DAA-induced SVR.
Author, Year
(Reference) Type of Study Design
De-Escalation/Withdrawal
of Oral Hypoglycemic
Agents, n/total (%)
De-Escalation/Withdrawal
of Insulin Therapy,
n/total (%)
Follow-Up
(EOT)
Hum et al. 2017
[14] Observational Retrospective 85/1630 (5.2%) 72/900 (8.0%) 12 months
Ciancio et al.
2018 [15] Observational Prospective 8/19 (41.2%) 13/46 (28.2%) 12 weeks
Dawood et al.
2017 [21] Clinical trial Open label 17/378 (4.4%) 61/378 (16.1%) 12 weeks
Morales et al.
2016 [22] Observational Retrospective 2/16 (12.5%) N.A. 24 weeks
Ikeda et al.
2017 [23] Observational Prospective 2/6 (33.3%) 1/6 (16.6%) 12 weeks
Bejg et al. 2018
[24] Observational Retrospective 2/26 (7.6%) 10/26 (38.4%) 24–44 weeks
Fabrizio et al.
2017 [25] Observational Retrospective 0/31 (0.0%) 1/16 (6.2%) 12–24 weeks
Pavone et al.
2016 [27] Observational Retrospective 2/10 (20.0%) 4/15 (26.6%) 8 weeks
Drazilova et al.
2018 [16] Observational Retrospective 0/13 (0.0%) 3/17 (17.6%) 12 weeks
Teegen et al.
2019 [30] Observational Retrospective N.A. 2/32 (6.25%) 30.6 months
HCV, hepatitis C virus; DAA, direct-acting antiviral agent; SVR, sustained virologic response; EOT, end of treatment;
N.A., not available.
In the study by Ciancio et al. [15], antidiabetic therapy was reduced, changed, or even suspended
only in patients with SVR (20.7%, p = 0.03). In detail, for 8 of the 19 patients (42.1%) taking oral
hypoglycemic therapy and 13 of the 46 (28.2%) on insulin therapy, administration of the drug was
decreased or suspended. It should be noted that these therapeutic variations occurred in the presence
of an average weight gain of 2.85 ± 4.33 kg among sustained responders. Of the 101 patients with
SVR, 9 (8.9%) had to have their therapeutic dosage increased compared to 1 nonresponder/untreated
patient (4.8%, p = 0.34). According to Dawood et al. [21], dosage reduction was observed only in
cured patients with concomitant improvement in glycometabolic control (292 patients). In this group,
78 patients (26.7%) had their antidiabetic therapy reduced (61 patients on insulin therapy, 17 treated
with gliclazide). Similar data were obtained by Pavone and colleagues [27]: 23% of patients with SVR
and glycemic amelioration had their antidiabetic treatment de-escalated. In detail, of the 29 diabetic
patients, 9 were treated with metformin, 1 with repaglinide, and 15 with insulin, while the remaining 4
were on diet therapy only. At the end of therapy, 2 of the 9 patients treated with metformin and 4 of
the 15 on insulin therapy had their dosage reduced. Of the 13 diabetic patients included in the study
by Ikeda et al. [23], 6 were treated with insulin, 6 with oral hypoglycemic agents, and 1 with diet alone.
Of the 12 patients on therapy, 3 (25%) had their pharmacological dosage reduced (1 on insulin therapy
and 2 treated with oral hypoglycemic agents). Hum and colleagues [14] showed that the percentage of
insulin-treated diabetic patients significantly decreased among those with SVR (from 41.3% to 38%)
compared to the control group (from 49.8% to 51%, p = 0.04). This reduction was not accompanied
by an increase in the proportion of patients treated with metformin, which, on the contrary, was also
reduced by 2.2%.
Regarding patients with OLT [24], of the 26 diabetic patients on antidiabetic therapy before
antiviral treatment, 24 received insulin and 2 insulin + oral hypoglycemic agents. At the end of
follow-up, only 16 received antidiabetic therapy, with suspension of this therapy in the remaining
10 (38%). Fabrizio and colleagues [25] did not show significant therapeutic variations despite the
reduction in glycemic values: of the 59 diabetic patients considered, 49 were on antidiabetic therapy
(16 on insulin, 31 on oral hypoglycemic agents, 2 on both drugs), but only 1 patient on insulin therapy
had the dosage reduced, while 2 of 4 patients with worsening glycemic control had to have their
dosage increased.
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In the study by Morales et al. [22], 2 of 16 diabetic patients (12%) receiving antihyperglycemic
medications had their insulin therapy de-escalated or suspended, but it is not known how many
were on insulin therapy and how many were on oral hypoglycemic agents. Of the 30 diabetic
patients on antidiabetic therapy recruited in the study of Drazilova et al. [16], 13 were given oral
hypoglycemic agents and 17 insulin. No reduction in oral therapy was observed, whereas 3 of 17 (17.6%)
insulin-treated patients had to have their dosage reduced for documented episodes of hypoglycemia.
Chaudhury and colleagues [32] and Stine and colleagues [31] did not show any significant therapeutic
modifications concerning antidiabetic treatment. On the contrary, in the study by Teegen et al. [30]
conducted on OLT patients, although no significant decrease in HbA1c levels was found, 2 of 32
patients had their insulin therapy suspended and a significant reduction in cumulative insulin dose
was observed (55.3 versus 38.2 U/d, p = 0.009).
In conclusion, most of the studies reporting improvements in glycometabolic control showed
reduction/suspension of antidiabetic therapy in a significant minority of patients; for this reason, it has
been suggested that diabetic patients with DAA-induced SVR should be carefully monitored regarding
their glycometabolic profile in order to avoid hypoglycemic episodes [15]. However, the heterogeneity
and incompleteness of the data do not allow us to assess the characteristics of the patients who obtained
this reduction/suspension or to identify a particular class of drugs particularly sensitive to this variation.
Furthermore, the brief follow-up reported by the studies does not permit us to determine whether
this modification was maintained over the long term. Future work will need to precisely evaluate
antidiabetic therapy modification in more depth as it represents a clinically meaningful endpoint.
3.4. Do DAA-Induced Glycemic Changes Determine a Significant Clinical Impact on the Outcome of DM and
its Complications?
During the IFN era, some studies [1,49,50] showed a significant decrease in overall liver- and
non-liver-related mortality in patients achieving SVR. This finding was recently confirmed by a French
prospective study [51] on 9895 patients with chronic hepatitis C, with 7344 treated with DAAs and
2551 untreated. At the end of follow-up, significant reductions in mortality (from any cause) and in the
incidence of hepatocellular carcinoma (HCC) in treated patients compared to untreated were found.
The decreased mortality from extrahepatic causes was probably due to the reduction of HCV-related
extrahepatic manifestations observed among patients with SVR [13].
Since IR and DM are now considered extrahepatic manifestations of HCV, a reduction in
complications of DM can be expected in diabetic patients with viral clearance. A Taiwanese study [52]
on diabetic patients with CHC treated with IFN showed a significant reduction in DM-related
complications, such as nephropathy, acute coronary artery disease, and stroke. However, several
methodological limitations of the study (exclusion of patients with significant co-morbidities, no
data on SVR, lack of details regarding patient characteristics and glycometabolic control) may have
influenced the results. Recently, an American study [53] on 723 diabetic patients and CHC treated with
IFN or DAAs showed a significant decrease in the incidence of acute coronary syndrome (HR = 0.36,
p < 0.001), advanced nephropathy (HR = 0.46, p < 0.001), stroke (HR = 0.34, p < 0.001), and retinopathy
(HR = 0.24, p < 0.001) in SVR patients compared to noncured or untreated patients. However, some
methodological weaknesses (lack of data on cardiovascular risk factors including smoking, cholesterol,
hypertension, adherence to diet, exercise, antiplatelet drugs) and the short duration of follow-up
(2.4–2.7 years) suggest caution regarding the reproducibility of the study. Moreover, in a previous
study [19], the authors showed that glycometabolic amelioration was not maintained over the long
term. How is it possible to achieve a significant decrease of DM-related complications without a
parallel persistent glycometabolic improvement?
A possible explanation could derive from the observation that viral clearance with DAAs
determines a significant improvement of extrahepatic diseases such as cardiovasculopathies and
nephropathies, regardless of the presence of DM. A recent American study [54] showed a significant
improvement in extrahepatic manifestations accompanying C virus infection in patients with CHC cured
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after therapy with DAAs. The percentage of diabetics in this population was less than 10%. In an Italian
study [55], a significant amelioration of carotid atherosclerosis, intima-media thickness, and carotid
thickening was found in 182 patients treated with DAAs; 20% were DM carriers. Improvement was not
influenced by cardiovascular risk factors such as DM, hypertension, hypercholesterolemia, and smoking.
These data suggest that the improvement of extrahepatic manifestations of HCV infection (in particular,
cardiovasculopathies and nephropathies) coinciding with the most frequent complications of diabetic
disease may improve after viral clearance due not only to glycometabolic control amelioration, but also
to other mechanisms yet to be established. In the case of nephropathy, it is likely that HCV eradication
may lead to an improvement in vasculitis–cryoglobulinemic damage [56,57]; the beneficial effect of
viral eradication on cardiovascular diseases may be derived from the disappearance of the systemic
inflammatory status [58], the decrease in TNF-α and IL-6 levels [59,60], and the increase in adiponectin
levels [61].
In conclusion, it is still unclear whether the reduction in complications of diabetic disease observed
after viral eradication is mainly due to glycometabolic improvement or to the direct beneficial effect
of viral clearance on extrahepatic sites. Further studies with appropriate follow-up are needed to
assess which is the key mechanism and whether this beneficial effect is maintained over the long term.
However, the data show that no improvement in DM is observed in patients with advanced fibrosis or
with long-term DM history, suggesting that there is a point of no return for the modifications in glucose
metabolism and, conversely, DM clinical outcome. For this reason, early identification of HCV-positive
diabetic patients is strongly recommended in order to start DAA therapy as early as possible.
3.5. What is the Clinical Impact of DAA-Induced SVR on The Incidence of HCC in Diabetic Patients?
Previous studies [62–64] conducted on IFN-treated patients showed that viral eradication resulted
in a significant reduction in liver-related events (hepatic decompensation, variceal bleeding, HCC) in
cirrhotic patients. Similarly, two studies [65,66] on noncirrhotic HCV-positive patients with IFN-induced
SVR demonstrated a decrease in the incidence of HCC. However, much evidence [63–72] suggests that
DM is an independent predictor of HCC, despite viral eradication obtained by IFN-based therapies.
Data from follow-up studies on patients with SVR after therapy with DAAs [51,73–81] are mainly
focused on the incidence of HCC in cured patients and are necessarily limited by the short follow-up.
In most of these studies [51,73–79], DM was not found to be an independent predictor of HCC in
patients with SVR; only two studies [80,81] confirmed the negative effect of diabetic disease on the
development of HCC after viral clearance. Unfortunately, the lack of data on the glycometabolic
control or the type of antidiabetic treatment limits the possibility of drawing definite conclusions.
Arase and colleagues [71] showed that maintaining HbA1c levels <7.0% during follow-up
significantly reduced the onset of HCC in diabetic patients with IFN-induced SVR. Similarly, some
studies [82–84] suggested a protective action of metformin therapy against HCC compared to other
antidiabetic treatments; an American study [85] showed a significant increase in the survival of DM
patients with cirrhosis of any etiology who did not have metformin therapy suspended or changed
with other types of antidiabetic therapy during follow-up.
In conclusion, the magnitude of risk reduction in HCC incidence found among diabetic patients
with SVR is probably comparable to that observed in nondiabetics; however, the discrepancy between
the data of the IFN period compared with the DAA period is puzzling and deserves further consideration.
It is likely that the difference in follow-up, which is generally longer in the IFN-based studies, may
have influenced the final results. However, the metabolic influence of DM on the residual HCC risk
in DAA-cured patients should be reconsidered thanks to recent studies [86,87] showing evidence of
HCV-induced epigenetic changes associated with HCC risk. According to these studies, the viral
epigenetic signature in the host genome is often irreversible, in particular in those patients with
advanced liver fibrosis.
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4. Conclusions
According to the vast majority of studies considered, the incidence of IR and DM appears to
decrease in CHC patients achieving SVR after DAA treatment, but the extent of this reduction is
questionable. In sustained responders with established DM, glycometabolic improvement is often
found with concomitant reduction of antidiabetic therapy in a significant subset of patients. However,
whether these beneficial effects are long lasting or just transient is still an unresolved issue; conversely,
the long-term clinical implications in terms of diabetic and hepatic outcomes of these biochemical and
pharmacological variations remain largely unknown. Therefore, a careful longitudinal monitoring
of these patients is needed before claiming any consolidated efficacy. Obviously, in order to arrive
at meaningful conclusions, it is necessary to await the results of long-term follow-up prospective
studies with an adequate number of patients. These results should include not only the biochemical
but also the clinical aspect; in other words, the main endpoint to be tested must focus on the question
of whether any improvement in glycemic control is going to have a major impact on the outcome of
liver and diabetic disease.
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